29620-62-0

Basic information

• Product Name: 1-PHENYL-PIPERAZIN-2-ONE
• Synonyms: 1-PHENYL-PIPERAZIN-2-ONE;CHEMBRDG-BB 4102112;INHd 42
• CAS NO: 29620-62-0
• Molecular Formula: C₁₀H₉N₃O
• Molecular Weight: 176.22
• Mol File: 29620-62-0.mol
• Article Data: 3

Chemical Properties

• Melting Point: 154.5 °C(Solv: benzene (71-43-2))
• Boiling Point: 394.867°C at 760 mmHg
• Flash Point: 192.609°C
• Appearance: /
• Density: 1.143g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 11.51±0.30(Predicted)
• CAS DataBase Reference: 1-PHENYL-PIPERAZIN-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-PHENYL-PIPERAZIN-2-ONE(29620-62-0)
• EPA Substance Registry System: 1-PHENYL-PIPERAZIN-2-ONE(29620-62-0)

Safety Data

• Hazardous Substances Data: 29620-62-0(Hazardous Substances Data)

Usage

General Description

1-PHENYL-PIPERAZIN-2-ONE, also known as PP2, is a chemical compound that belongs to the group of piperazine derivatives. It is a white crystalline powder with a molecular formula of C10H12N2O and a molecular weight of 176.22 g/mol. PP2 has gained attention for its potential therapeutic applications, particularly in the field of neuroscience. It is known to act as an inhibitor of various enzymes and receptors in the brain, and studies have shown its potential to modulate signaling pathways involved in neurological disorders. Additionally, PP2 has been investigated for its anti-anxiety and anti-depressant effects, making it a promising compound for further research in the development of new pharmacological treatments for mental health conditions.

InChI:InChI=1/C10H12N2O/c13-10-8-11-6-7-12(10)9-4-2-1-3-5-9/h1-5,11H,6-8H2

Upstream product

• 21233-61-4 quinoline-4-carboxylic acid methyl ester 
• 10447-29-7 ethyl quinoline-4-carboxylate 
• 4363-93-3 quinoline-4-carboxaldehyde 
• 2973-27-5 quinoline-4-carbonitrile 

Downstream Products

• 92119-01-2 N-phenylquinoline-4-carboxamide 
• 108477-75-4 quinoline-4-carboxylic acid-(4-dimethylamino-benzylidenehydrazide) 
• 107413-58-1 quinoline-4-carboxylic acid-(4-hydroxy-benzylidenehydrazide) 
• 108370-04-3 quinoline-4-carboxylic acid-(4-acetylamino-benzylidenehydrazide) 

Relevant articles and documents

Ring-substituted quinolines. Part 2: Synthesis and antimycobacterial activities of ring-substituted quinolinecarbohydrazide and ring-substituted quinolinecarboxamide analogues

The antimycobacterial activities of ring-substituted quinolinecarbohydrazide and ring-substituted quinolinecarboxamide analogues (series 1-5) against M. tuberculosis H37Rv strains are described. The most effective analogues have exhibited excellent antimy

Antiaging activity, molecular docking, and prediction of percutaneous absorption parameters of quinoline–hydrazone hybrids

The application of antiaging agents can contribute to the prevention and control of skin photoaging. In the current research, nine quinoline–hydrazone hybrids were synthesized to obtain biologically active compounds as possible antiaging agents. The compounds were tested through a comprehensive in vitro evaluation of antielastase, anticollagenase, and antihyaluronidase activities along with the determination of their potential to quench reactive oxygen species (ROS) by the ORAC method. The selected hybrids were subsequently tested on human dermal fibroblasts (HDF) to reveal possible UVB photoprotective activity. The most potent antiaging protection of all the prepared compounds was shown by the trihydroxylated quinoline–hydrazones 5 and 9, which showed the best collagenase inhibition (IC50 = 39.4 and 45.6 μM, respectively). Compound 5 also showed activity against elastase and hyaluronidase (IC50 = 164.2 and 318.8 μM, respectively). The molecular docking results suggest that the difference of inhibition between 5 and 9 is principally attributed to the hydrogen bonds interactions in the residues His218 and His228, and Zn atom in collagenase, Val216 in elastase and Tyr75 in hyaluronidase. In addition, compounds 5 and 9 were able to significantly protect human skin cells from UVB radiation in vitro. These compounds significantly decreased UVB-induced MMP-1 and ROS production and inhibited the suppression of type I procollagen synthesis in cultured HDF. The in silico dermatopharmacokinetic parameters showed promising results. Therefore, our study presented promising results for antiaging drug discovery, focusing on quinoline–hydrazone hybrids as dual inhibitors of skin aging-related enzymes, antioxidants, and inhibitors of the biological effects of UVB irradiation.